Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peghini, P. L.
Right arrow Articles by Jensen, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peghini, P. L.
Right arrow Articles by Jensen, R. T.
Clinical Cancer Research Vol. 8, 2273-2285, July 2002
© 2002 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Overexpression of Epidermal Growth Factor and Hepatocyte Growth Factor Receptors in a Proportion of Gastrinomas Correlates with Aggressive Growth and Lower Curability

Paolo L. Peghini, Michiko Iwamoto, Mark Raffeld, Yuan-Jia Chen, Stephan U. Goebel, Jose Serrano and Robert T. Jensen1

Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases [P. L. P., M. I., S. U. G., J. S., R. T. J.] and Hematopathology Section, Laboratory of Pathology, National Cancer Institute [M. R.], NIH, Bethesda, Maryland 20892

Purpose: Growth factor receptor expression and activation, particularly for epidermal growth factor (EGF) and hepatocyte growth factor (HGF), in many endocrine and nonendocrine tumors is important in determining tumor recurrence, growth, and aggressiveness. Whether this is true of neuroendocrine tumors such as gastrinomas is unclear.

Experimental Design: To address this question, we analyzed the extent of EGFR and HGFR expression in gastrinomas from 38 patients with Zollinger-Ellison syndrome and correlated it with clinical and tumor characteristics. EGFR (n = 38) and HGFR (n = 22) mRNA levels were determined by competitive PCR, and immunohistochemistry was performed on a subset.

Results: In each of the gastrinomas studied, detectable levels of EGFR and HGFR mRNA were present. Low levels of EGFR protein expression were detected in 40% of gastrinomas and HGFR protein expression in 90%. EGFR mRNA expression varied by 1050-fold and HGFR by 375-fold. Eighteen percent of gastrinomas overexpressed EGFR mRNA and 14% overexpressed HGFR mRNA, compared with normal pancreas. Maximal EGFR and HGFR mRNA levels were 4- and 1.2-fold increased and correlated with the presence of liver metastases (P = 0.034) and decreased long-term curability (P = 0.027) but not tumor location, size, or tumor functional characteristics.

Conclusions: These above results indicate that EGFR and HGFR mRNA are universally expressed in gastrinomas. Furthermore, each is overexpressed in a minority (15–20%) of the gastrinomas, and the overexpression correlates with aggressive growth and lower curability.




This article has been cited by other articles:


Home page
EndocrinologyHome page
M. Hayashi, M. Sakata, T. Takeda, M. Tahara, T. Yamamoto, Y. Okamoto, R. Minekawa, A. Isobe, M. Ohmichi, K. Tasaka, et al.
Up-Regulation of c-met Protooncogene Product Expression through Hypoxia-Inducible Factor-1{alpha} Is Involved in Trophoblast Invasion under Low-Oxygen Tension
Endocrinology, November 1, 2005; 146(11): 4682 - 4689.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
P. M. Weinberger, Z. Yu, D. Kowalski, J. Joe, P. Manger, A. Psyrri, and C. T. Sasaki
Differential Expression of Epidermal Growth Factor Receptor, c-Met, and HER2/neu in Chordoma Compared With 17 Other Malignancies
Arch Otolaryngol Head Neck Surg, August 1, 2005; 131(8): 707 - 711.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Furukawa, M. Raffeld, C. Mateo, A. Sakamoto, T. W. Moody, T. Ito, D. J. Venzon, J. Serrano, and R. T. Jensen
Increased Expression of Insulin-Like Growth Factor I and/or Its Receptor in Gastrinomas Is Associated with Low Curability, Increased Growth, and Development of Metastases
Clin. Cancer Res., May 1, 2005; 11(9): 3233 - 3242.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. E. Hansel, A. Rahman, M. House, R. Ashfaq, K. Berg, C. J. Yeo, and A. Maitra
Met Proto-Oncogene and Insulin-Like Growth Factor Binding Protein 3 Overexpression Correlates with Metastatic Ability in Well-Differentiated Pancreatic Endocrine Neoplasms
Clin. Cancer Res., September 15, 2004; 10(18): 6152 - 6158.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
O. M. Fischer, S. Giordano, P. M. Comoglio, and A. Ullrich
Reactive Oxygen Species Mediate Met Receptor Transactivation by G Protein-coupled Receptors and the Epidermal Growth Factor Receptor in Human Carcinoma Cells
J. Biol. Chem., July 9, 2004; 279(28): 28970 - 28978.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.